Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the sale, the chief executive officer owned 2,272,500 shares in the company, valued at $221,455,125. The trade was a 0.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

iRadimed Trading Up 2.3%

Shares of IRMD opened at $101.53 on Thursday. iRadimed Corporation has a 52 week low of $47.48 and a 52 week high of $102.28. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 61.53 and a beta of 1.09. The stock has a 50 day moving average of $93.70 and a 200-day moving average of $77.79.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.04. The firm had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, sell-side analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio is currently 41.21%.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Lake Street Capital restated a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Wall Street Zen downgraded iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Roth Capital set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Zacks Research raised iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.33.

Institutional Trading of iRadimed

Several large investors have recently added to or reduced their stakes in IRMD. CWM LLC raised its stake in iRadimed by 62.2% during the 3rd quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 211 shares in the last quarter. Quarry LP acquired a new position in shares of iRadimed during the third quarter valued at $40,000. State of Alaska Department of Revenue bought a new stake in shares of iRadimed during the third quarter valued at about $47,000. Tower Research Capital LLC TRC lifted its holdings in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the period. Finally, USA Financial Formulas acquired a new stake in iRadimed in the fourth quarter worth about $82,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.